Author: redapost

According to thierry Ehrmann Founder and CEO of Artprice: ‘For multiple reasons, 2019 is commencing with an excellent outlook for Artprice and its loyal shareholders over the last 21 years’.

     (Logo: https://mma.prnewswire.com/media/644091/Artprice_Logo.jpg )

     (Photo: https://mma.prnewswire.com/media/802372/Artprice_com.jpg )

The first exceptionally positive news is our penetration of the Chinese Art Market with its huge potential to generate new customers for Artprice. This move will substantially boost our sales turnover via the sale of Artprice subscriptions offered in China as of 1 January 2019 via Artron.net, our institutional partner. Artron is widely recognised as the most powerful actor on the Chinese Art Market.

The second positive news is that a week ago Artprice signed a deal with the most powerful press network in the world that will project Artprice”s hot market news to 1.8 billion people on a weekly basis.

This exceptional partnership has been concluded with the world”s leading newswire, Cision. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact (see Cision”s official press release Artprice and Cision Enter Distribution Partnership at https://www.prnewswire.com/news-releases/artprice-and-cision-enter-distribution-partnership-300770437.html (Cision is listed on the NYSE, code CISN).

This partnership will allow Artprice to project highly pertinent Art Market News and Information on a weekly basis. Cision”s electronic newswire will communicate all of Artprice”s unique market indices… the Artprice100®, the Artprice Global Index®, the AMCI®, etc… in real time.

By reaching more than 1.8 billion targeted people in 19 languages on 5 continents (representing 90% of the world”s GDP), this move unquestionably strengthens Artprice”s position as World Leader in Art Market Information.

Thanks to this massive news & info distribution agreement, Artprice will project its unique know-how and understanding of the Art Market, reaching new art fans, collectors and professionals whose geographical location previously hindered an economical distribution of the Artprice brand and its databases.

This obstacle has now been eliminated, allowing Artprice to be the ”glocal reference for the Art Market. (”Glocal” is a combination of two words: global and local. It is often used to indicate a global marketing strategy with local relays. Hence the dictum ‘Think global, act local‘).

Artprice was the global leader… but there were still a number of ”local” economic ”white zones”.

As of 1 January 2019, Artprice, with its loyal institutional partner Artron, will irrigate the 34 divisions / provinces of the People”s Republic of China with its paid databank content.

With Cision, no territory – whatever the continent – will escape Artprice… now a truly ”Glocal” and unique reference for the Art Market.

In short, with Cision, Artprice has become unavoidable at the global level for all matters relating to the Art Market because Cision has the world”s largest and most reliable press release network that can identify key influencers. Art Press Agency® and Artmarket.com is now the world”s leading art press agency dedicated to the Art Market.

About Cision : 

Cision Ltd. (NYSE:  CISN) is a leading global provider of earned media software and services to public relations and marketing communications professionals. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact. Cision has over 4,000 employees with offices in 19 countries throughout the Americas, EMEA, and APAC. For more information about its award-winning products and services, including the Cision Communications Cloud®

About Artprice: 

Founded by thierry Ehrmann (see Who”s who certified Biography ) (c) https://imgpublic.artprice.com/img/wp/sites/11/2018/10/bio-2019-whos-who-thierry-ehrmann.pdf ).

Artprice is listed on the Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Dicover Artprice in video: https://www.artprice.com/video

Artprice is the global leader in art price and art index databanks. It has over 30 million indices and auction results covering more than 700,000 artists. Artprice Images® gives unlimited access to the largest Art Market resource in the world: a library of 126 million images or prints of artworks from the year 1700 to the present day, along with comments by Artprice”s art historians.

Artprice permanently enriches its databanks with information from 6,300 auctioneers and it publishes a constant flow of art market trends for the world”s principal news agencies and approximately 7,200 international press publications. For its 4,500,000 members, Artprice gives access to the world”s leading Standardised Marketplace for buying and selling art. Artprice is preparing its blockchain for the Art Market. It is BPI-labelled (scientific national French label) Artprice”s Global Art Market Annual Report for 2017 published last March 2018: https://www.artprice.com/artprice-reports/the-art-market-in-2017

Artprice is associated with Artron Group the Chinese leader in the Art Market, its solid institutional partner. 

About the Artron Group: 

‘Artron Art Group (Artron), a comprehensive cultural industrial group founded in 1993 by Wan jie, is committed to inheriting, enhancing and spreading art value. Based on abundant art data, Artron provides art industry and art fans with professional service and experience of quality products by integrated application of IT, advanced digital science and innovative crafts and materials. Having produced more than 60,000 books and auction catalogues, Artron is the world”s largest art book printer with a total print volume of 300 million a year. It has more than 3 million professional members in the arts sector and an average of 15 million daily visits, making it the world”s leading art website. Founded in 1993by Wan Jie, the Artron Art Group is celebrating its 25th anniversary this year. It is the first choice for art professionals, investors, collectors and art fans in general wishing to discover and/or participate in the art world or the art market. Founded in 1993, Artron Art Group is celebrating its 25th anniversary this year.’

Artron”s Web: http://www.Artron.net

Artprice”s Contemporary Art Market Annual Report for 2017 – free access at: https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2017

Artprice”s press releases:

http://serveur.serveur.com/Press_Release/pressreleaseen.htm

https://twitter.com/artpricedotcom

Artmarket News:

https://twitter.com/artpricedotcom & https://twitter.com/artmarketdotcom

https://www.facebook.com/artpricedotcom 3.4 million subscribers

http://artmarketinsight.wordpress.com/

Discover the Alchemy and the universe of Artprice http://web.artprice.com/video, which headquarters are the famous Museum of Contemporary Art, the Abode of Chaos:

http://goo.gl/zJssd

https://vimeo.com/124643720

The Contemporary Art Museum The Abode of Chaos  

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999  3.4 million subscribers

Contact: thierry Ehrmann,  ir@artprice.com

PARIS, December 26, 2018 /PRNewswire/ —

Read Full Article

According to thierry Ehrmann Founder and CEO of Artprice: ‘For multiple reasons, 2019 is commencing with an excellent outlook for Artprice and its loyal shareholders over the last 21 years’.

     (Logo: https://mma.prnewswire.com/media/644091/Artprice_Logo.jpg )

     (Photo: https://mma.prnewswire.com/media/802372/Artprice_com.jpg )

The first exceptionally positive news is our penetration of the Chinese Art Market with its huge potential to generate new customers for Artprice. This move will substantially boost our sales turnover via the sale of Artprice subscriptions offered in China as of 1 January 2019 via Artron.net, our institutional partner. Artron is widely recognised as the most powerful actor on the Chinese Art Market.

The second positive news is that a week ago Artprice signed a deal with the most powerful press network in the world that will project Artprice”s hot market news to 1.8 billion people on a weekly basis.

This exceptional partnership has been concluded with the world”s leading newswire, Cision. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact (see Cision”s official press release Artprice and Cision Enter Distribution Partnership at https://www.prnewswire.com/news-releases/artprice-and-cision-enter-distribution-partnership-300770437.html (Cision is listed on the NYSE, code CISN).

This partnership will allow Artprice to project highly pertinent Art Market News and Information on a weekly basis. Cision”s electronic newswire will communicate all of Artprice”s unique market indices… the Artprice100®, the Artprice Global Index®, the AMCI®, etc… in real time.

By reaching more than 1.8 billion targeted people in 19 languages on 5 continents (representing 90% of the world”s GDP), this move unquestionably strengthens Artprice”s position as World Leader in Art Market Information.

Thanks to this massive news & info distribution agreement, Artprice will project its unique know-how and understanding of the Art Market, reaching new art fans, collectors and professionals whose geographical location previously hindered an economical distribution of the Artprice brand and its databases.

This obstacle has now been eliminated, allowing Artprice to be the ”glocal reference for the Art Market. (”Glocal” is a combination of two words: global and local. It is often used to indicate a global marketing strategy with local relays. Hence the dictum ‘Think global, act local‘).

Artprice was the global leader… but there were still a number of ”local” economic ”white zones”.

As of 1 January 2019, Artprice, with its loyal institutional partner Artron, will irrigate the 34 divisions / provinces of the People”s Republic of China with its paid databank content.

With Cision, no territory – whatever the continent – will escape Artprice… now a truly ”Glocal” and unique reference for the Art Market.

In short, with Cision, Artprice has become unavoidable at the global level for all matters relating to the Art Market because Cision has the world”s largest and most reliable press release network that can identify key influencers. Art Press Agency® and Artmarket.com is now the world”s leading art press agency dedicated to the Art Market.

About Cision : 

Cision Ltd. (NYSE:  CISN) is a leading global provider of earned media software and services to public relations and marketing communications professionals. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact. Cision has over 4,000 employees with offices in 19 countries throughout the Americas, EMEA, and APAC. For more information about its award-winning products and services, including the Cision Communications Cloud®

About Artprice: 

Founded by thierry Ehrmann (see Who”s who certified Biography ) (c) https://imgpublic.artprice.com/img/wp/sites/11/2018/10/bio-2019-whos-who-thierry-ehrmann.pdf ).

Artprice is listed on the Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Dicover Artprice in video: https://www.artprice.com/video

Artprice is the global leader in art price and art index databanks. It has over 30 million indices and auction results covering more than 700,000 artists. Artprice Images® gives unlimited access to the largest Art Market resource in the world: a library of 126 million images or prints of artworks from the year 1700 to the present day, along with comments by Artprice”s art historians.

Artprice permanently enriches its databanks with information from 6,300 auctioneers and it publishes a constant flow of art market trends for the world”s principal news agencies and approximately 7,200 international press publications. For its 4,500,000 members, Artprice gives access to the world”s leading Standardised Marketplace for buying and selling art. Artprice is preparing its blockchain for the Art Market. It is BPI-labelled (scientific national French label) Artprice”s Global Art Market Annual Report for 2017 published last March 2018: https://www.artprice.com/artprice-reports/the-art-market-in-2017

Artprice is associated with Artron Group the Chinese leader in the Art Market, its solid institutional partner. 

About the Artron Group: 

‘Artron Art Group (Artron), a comprehensive cultural industrial group founded in 1993 by Wan jie, is committed to inheriting, enhancing and spreading art value. Based on abundant art data, Artron provides art industry and art fans with professional service and experience of quality products by integrated application of IT, advanced digital science and innovative crafts and materials. Having produced more than 60,000 books and auction catalogues, Artron is the world”s largest art book printer with a total print volume of 300 million a year. It has more than 3 million professional members in the arts sector and an average of 15 million daily visits, making it the world”s leading art website. Founded in 1993by Wan Jie, the Artron Art Group is celebrating its 25th anniversary this year. It is the first choice for art professionals, investors, collectors and art fans in general wishing to discover and/or participate in the art world or the art market. Founded in 1993, Artron Art Group is celebrating its 25th anniversary this year.’

Artron”s Web: http://www.Artron.net

Artprice”s Contemporary Art Market Annual Report for 2017 – free access at: https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2017

Artprice”s press releases:

http://serveur.serveur.com/Press_Release/pressreleaseen.htm

https://twitter.com/artpricedotcom

Artmarket News:

https://twitter.com/artpricedotcom & https://twitter.com/artmarketdotcom

https://www.facebook.com/artpricedotcom 3.4 million subscribers

http://artmarketinsight.wordpress.com/

Discover the Alchemy and the universe of Artprice http://web.artprice.com/video, which headquarters are the famous Museum of Contemporary Art, the Abode of Chaos:

http://goo.gl/zJssd

https://vimeo.com/124643720

The Contemporary Art Museum The Abode of Chaos  

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999  3.4 million subscribers

Contact: thierry Ehrmann,  ir@artprice.com

PARIS, December 26, 2018 /PRNewswire/ —

Read Full Article

According to thierry Ehrmann Founder and CEO of Artprice: ‘For multiple reasons, 2019 is commencing with an excellent outlook for Artprice and its loyal shareholders over the last 21 years’.

     (Logo: https://mma.prnewswire.com/media/644091/Artprice_Logo.jpg )

     (Photo: https://mma.prnewswire.com/media/802372/Artprice_com.jpg )

The first exceptionally positive news is our penetration of the Chinese Art Market with its huge potential to generate new customers for Artprice. This move will substantially boost our sales turnover via the sale of Artprice subscriptions offered in China as of 1 January 2019 via Artron.net, our institutional partner. Artron is widely recognised as the most powerful actor on the Chinese Art Market.

The second positive news is that a week ago Artprice signed a deal with the most powerful press network in the world that will project Artprice”s hot market news to 1.8 billion people on a weekly basis.

This exceptional partnership has been concluded with the world”s leading newswire, Cision. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact (see Cision”s official press release Artprice and Cision Enter Distribution Partnership at https://www.prnewswire.com/news-releases/artprice-and-cision-enter-distribution-partnership-300770437.html (Cision is listed on the NYSE, code CISN).

This partnership will allow Artprice to project highly pertinent Art Market News and Information on a weekly basis. Cision”s electronic newswire will communicate all of Artprice”s unique market indices… the Artprice100®, the Artprice Global Index®, the AMCI®, etc… in real time.

By reaching more than 1.8 billion targeted people in 19 languages on 5 continents (representing 90% of the world”s GDP), this move unquestionably strengthens Artprice”s position as World Leader in Art Market Information.

Thanks to this massive news & info distribution agreement, Artprice will project its unique know-how and understanding of the Art Market, reaching new art fans, collectors and professionals whose geographical location previously hindered an economical distribution of the Artprice brand and its databases.

This obstacle has now been eliminated, allowing Artprice to be the ”glocal reference for the Art Market. (”Glocal” is a combination of two words: global and local. It is often used to indicate a global marketing strategy with local relays. Hence the dictum ‘Think global, act local‘).

Artprice was the global leader… but there were still a number of ”local” economic ”white zones”.

As of 1 January 2019, Artprice, with its loyal institutional partner Artron, will irrigate the 34 divisions / provinces of the People”s Republic of China with its paid databank content.

With Cision, no territory – whatever the continent – will escape Artprice… now a truly ”Glocal” and unique reference for the Art Market.

In short, with Cision, Artprice has become unavoidable at the global level for all matters relating to the Art Market because Cision has the world”s largest and most reliable press release network that can identify key influencers. Art Press Agency® and Artmarket.com is now the world”s leading art press agency dedicated to the Art Market.

About Cision : 

Cision Ltd. (NYSE:  CISN) is a leading global provider of earned media software and services to public relations and marketing communications professionals. Cision”s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact. Cision has over 4,000 employees with offices in 19 countries throughout the Americas, EMEA, and APAC. For more information about its award-winning products and services, including the Cision Communications Cloud®

About Artprice: 

Founded by thierry Ehrmann (see Who”s who certified Biography ) (c) https://imgpublic.artprice.com/img/wp/sites/11/2018/10/bio-2019-whos-who-thierry-ehrmann.pdf ).

Artprice is listed on the Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Dicover Artprice in video: https://www.artprice.com/video

Artprice is the global leader in art price and art index databanks. It has over 30 million indices and auction results covering more than 700,000 artists. Artprice Images® gives unlimited access to the largest Art Market resource in the world: a library of 126 million images or prints of artworks from the year 1700 to the present day, along with comments by Artprice”s art historians.

Artprice permanently enriches its databanks with information from 6,300 auctioneers and it publishes a constant flow of art market trends for the world”s principal news agencies and approximately 7,200 international press publications. For its 4,500,000 members, Artprice gives access to the world”s leading Standardised Marketplace for buying and selling art. Artprice is preparing its blockchain for the Art Market. It is BPI-labelled (scientific national French label) Artprice”s Global Art Market Annual Report for 2017 published last March 2018: https://www.artprice.com/artprice-reports/the-art-market-in-2017

Artprice is associated with Artron Group the Chinese leader in the Art Market, its solid institutional partner. 

About the Artron Group: 

‘Artron Art Group (Artron), a comprehensive cultural industrial group founded in 1993 by Wan jie, is committed to inheriting, enhancing and spreading art value. Based on abundant art data, Artron provides art industry and art fans with professional service and experience of quality products by integrated application of IT, advanced digital science and innovative crafts and materials. Having produced more than 60,000 books and auction catalogues, Artron is the world”s largest art book printer with a total print volume of 300 million a year. It has more than 3 million professional members in the arts sector and an average of 15 million daily visits, making it the world”s leading art website. Founded in 1993by Wan Jie, the Artron Art Group is celebrating its 25th anniversary this year. It is the first choice for art professionals, investors, collectors and art fans in general wishing to discover and/or participate in the art world or the art market. Founded in 1993, Artron Art Group is celebrating its 25th anniversary this year.’

Artron”s Web: http://www.Artron.net

Artprice”s Contemporary Art Market Annual Report for 2017 – free access at: https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2017

Artprice”s press releases:

http://serveur.serveur.com/Press_Release/pressreleaseen.htm

https://twitter.com/artpricedotcom

Artmarket News:

https://twitter.com/artpricedotcom & https://twitter.com/artmarketdotcom

https://www.facebook.com/artpricedotcom 3.4 million subscribers

http://artmarketinsight.wordpress.com/

Discover the Alchemy and the universe of Artprice http://web.artprice.com/video, which headquarters are the famous Museum of Contemporary Art, the Abode of Chaos:

http://goo.gl/zJssd

https://vimeo.com/124643720

The Contemporary Art Museum The Abode of Chaos  

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999  3.4 million subscribers

Contact: thierry Ehrmann,  ir@artprice.com

PARIS, December 26, 2018 /PRNewswire/ —

Read Full Article

FN Media Group Presents Safehaven.com News Commentary

Wayland Group (WAYL.CN – MRRCF) can produce cannabis at $0.05 a gram in South American and sells cannabis for up to $16 in some European markets. How do they do it? With a simple, but powerful business strategy. Mentioned in today”s commentary includes: Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group (NASDAQ: CRON) (TSX: CRON), Aurora Cannabis (NYSE: ACB) (TSX: ACB), Emblem Corp. (OTC: EMMBF) (TSX.V: EMC), THC Biomed International (OTC: THCBF) (CSE: THC).

Wayland focuses on the lowest cost production methods. Produce product in countries with weaker currencies. Sell into the highest-paying markets that have strong currencies. And don”t think because they focus on lowering the cost of production that this is a lower grade product.

Because the Wayland Group (WAYL.CN ; MRRCF) just hit one of the greatest benchmarks a cannabis producer can hit. They”ve achieved GMP Certification (Good Manufacturing Practice). The only other 4 Canadian cannabis producers who hit this milestone are industry giants now.

If you know cannabis investing, then you know these names:

  • Aurora Cannabis Inc now about $5.64 a share
  • Cronos Group Inc now about $11.35 a share
  • Canopy Growth Corporation now about $29.61 a share
  • Tilray, Inc now about $74 a share

Wayland has joined them as one of only 5 Canadian producers who are GMP certified producers for the European Union. It”s impressive because Wayland”s a much smaller company.

Why does the ability to sell into the European Union matter? Two reasons: First, because medical cannabis in Europe commands some of the highest prices per gram in the world. The insurance coverage in Europe for medical use of cannabis is widespread. Second, because of the currency exchange. Canadian producers are bearing production costs in Canadian dollars but selling in Euros. (One euro is worth roughly $1.52 Canadian.)

That is part of the reason why, in Canada, Wayland sells cannabis at an average $5.56 per gram. But in Europe Wayland (WAYL.CN; MRRCF) can sell it for up to $16 Canadian dollars per gram. That”s three times the price.

Wayland has taken this idea of low-cost production and high buying markets to an extreme their investors love

They automated production to reduce their workforce from 500 people down to just 26. And payroll costs can add enormous amounts to a company”s overhead (and eat away at margins).

For instance, the minimum wage in Canada is $14 per hour. And paying 500 people at $14 per hour for a 40-hour work week means you”re paying $280,000 per week in payroll. Over 52 weeks that balloons to over $14 million in payroll costs. But not at Wayland. By reducing staff to just 25 employees at a production facility through automation they”ve dramatically reduced costs.

The 4 cost-cutting secrets to these gross margins

  1. Technology is on their side

Wayland uses an AI Master Grower so they only need a fraction of the workforce of many labor intensive operations.

This cannabis producer has a world-class tech team. By using artificial intelligence and big data they have automated cannabis production to an astounding degree. Some of their competitors need up to 500 employees to match the production of Wayland”s staff of 26. That”s 5% of some competitors” workforce.

  2. Smart strategic alliances

The AI Master Grower is powered by Rockwell Automation, and Wayland is the first cannabis company to embrace automation as a key feature of the cultivation process. With a tiny staff, Wayland can produce thousands of grams of cannabis for export.
That brings production costs way, way down. At the Langton facility in Canada, Wayland deploys the AI Master Grower to oversee 365,000 square feet and a potential annual capacity of 95,000 kilos.

  3. They cut energy costs to a fraction

When cannabis was illegal, one way police would look for growers was to find places with massive energy costs. That”s because traditional production methods require enormous amounts of energy. Those costs cut into profits.
Wayland went through every step and cost of production to find ways to cut costs. The company can cut big costs by embracing renewable energy sources and energy efficient practices. Their facilities are powered by natural gas co-generation and they utilize recycled water for their hydroponics, which cuts down on waste that can accumulate from bad growth practices. The company has worked out a quick-dry method with former JPL scientists.

  4. VESIsorb Tech means customers need to take less to get the same effect

Wayland has also brought advances in pharmaceuticals to cannabis cultivation. The company has deployed VESIsorb medical tech for its cannabis products.
When cannabinoids are ingested, they enter the body but tend to get clumped in the digestive system, interfering with absorption and diminishing the overall effect. VESIsorb disperses the CBD molecules so they”re easier to absorb, providing higher and more immediate levels of CBD absorption. The company”s automated production techniques, energy efficiency and global reach means it can get its product to the market at a cost lower than many competitors all around the world.

In 2019, cannabis will enter the mainstream. Demand is set to grow. And Wayland”s low production costs will give it an edge over its competitors.

Savvy investors need pay attention.

Other companies transforming the cannabis sector:

Aurora Cannabis (NYSE:ACB) (TSX:ACB)

Recently, Aurora sealed a supply deal with Mexico”s Farmacias Magistrales SA, the country”s first and, for now, at least, only federally licensed importer of raw materials containing THC.

In an announcement from Aurora, the company stated that the deal ‘firmly establishes Aurora”s first-mover advantage in one of the world”s most populous countries, where more than 130 million people will have federally legal access to a range of Aurora”s non-flower medical cannabis products containing THC.’

Cronos Group (NASDAQ: CRON) (TSX: CRON)

The Canadian firm, though primarily an equity investor, has made some major moves in recent years, wheeling and dealing with some of the hottest names in the sector. Because of its forward-thinking attitude, it has drawn the attention of many major mainstream players, including the company behind Marlboro, Altria Group.

On December 7th, rumors were finally confirmed when Cronos made the official announcement of a C$2.4 billion strategic investment from Altria. ‘Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth,’ said Cronos Group”s Mike Gorenstein, Chairman, President and Chief Executive Officer.

Canopy Growth Corporation (NYSE:CGC) (TSX:WEED)

Canopy has not stopped making moves in the market, most recently swallowing up renowned vaporizer producer Stor & Bickel Gmbh & Co., the creator of the iconic Volcano® Medic and the Mighty® Medic devices

The €145 million all-cash deal makes it one of the largest in the marijuana sector this year, and Canopy Growth is not likely to stop there.

Emblem Corp. (OTCMKTS:EMMBF) (TSX.V: EMC)

Recently, Emblem completed testing on a new oral extended release product with partner Canntab Therapeutics. With the successful tests, the companies announced that they will be moving forward into clinical trials.

In addition to its advancements in the medial field, Emblem is also working towards a safer community, partnering with DriveABLE in an effort to curb accidents from impaired drivers. Nick Dean, CEO, Emblem Corp. explained, ‘Impairment – whether from alcohol, cannabis, fatigue, underlying medical conditions, or narcotics – is a serious issue that affects safety on roads and in the workplace.’

THC Biomed International (OTCMKTS:THCBF) (CSE:THC)

THC Biomed operates as a licensed producer under Canada”s Marihuana for Medical Purposes Regulations. It is also engaged in the research & development of the products and services to medical marijuana.

THC Biomed”s recently announced a new THC-based beverage, aiming to appeal to a broader range of consumers. John Miller CEO explained, ‘THC has conducted extensive research on cannabis edibles and beverages and I have found our product to be exclusive in its category.’

Though THC Biomed may be smaller than some of its more well-known competitors, it is just as ambitious. And it”s beginning to pay off. Earlier this month, the company made its first shipment of cannabis products to its Saskatchewan partner, and is rapidly expanding its holdings, with two new strata lot purchases, adding to its growing array of assets.

By. Joao Piexe

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that cannabis use and sales will grow as currently predicted; Wayland”s intended acquisition of various foreign companies and expansion into international markets; Wayland”s plans to bring automation and the latest technology to projects in various locations throughout the world; that it could be granted growing licenses; that Wayland can close on its announced purchases and joint ventures; that through efficiency and technology Wayland can substantially lower its production costs below competitors; that Wayland can sell its product at huge gross margins; that Wayland will create a range of cannabis consumer brands, to be distributed through their own digital platforms and retail facilities; that Wayland can successfully integrate pharmaceutical breakthroughs into its products; that Wayland can achieve its sales targets and gross profit margins as planned; and that it will be able to carry out its business plans.

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Wayland. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; announced or expected acquisitions or joint ventures may not close because of inability to come to final terms, or inability to obtain regulatory compliance; potential future competition in the markets Wayland operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; interruption or failure of information or other technology systems; the cannabis market may not grow as expected; Wayland”s technology and drive for efficiency may not achieve the expected results and its accomplishments may be limited; Wayland may not successfully develop a cannabis consumer brand; and it may not be successful in developing a cannabis based treatment for medical uses; even if it develops a successful treatment, it may not be able to protect its intellectual property; its patent applications may be rejected or successfully challenged; Wayland”s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; and regulatory risks relating to Wayland”s business, financings and strategic acquisitions.

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Safehaven.com, Leacap Ltd, and their owners, managers, employees, and assigns (collectively ‘the Company’) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Wayland fifty-eight thousand three hundred thirty three US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Wayland to conduct investor awareness advertising and marketing for Wayland. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The owner of Safehaven.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of Safehaven.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don”t trade with money you can”t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ‘Forward-looking statements’ describe future expectations, plans, results, or strategies and are generally preceded by words such as ‘may’, ‘future’, ‘plan’ or ‘planned’, ‘will’ or ‘should’, ‘expected,’ ‘anticipates’, ‘draft’, ‘eventually’ or ‘projected’. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company”s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact – FN Media Group LLC
e-mail:  editor@financialnewsmedia.com  
U.S. Phone: +1(954)345-0611

LONDON, December 21, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the ‘treatment of frontotemporal dementia’. The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.

     (Logo: http://mma.prnewswire.com/media/609663/TauRx_Therapeutics_Logo.jpg )

LMTX® is the first protein aggregation inhibitor to reach Phase 3 clinical development for treatment of neurodegenerative diseases of the brain and was developed by TauRx based on nearly 30 years of research. Protein aggregation inhibitors work by undoing the protein aggregations in the brain that are now widely accepted to drive the development of dementia. This unique mechanism of action can potentially slow the rate of spread of the underlying disease pathology and thereby help to preserve patients” cognition, function and quality of life. Primarily focused at tangled sub-units of the tau protein, the active moiety in LMTX® has also shown to be active against aggregations of the TDP-43 protein; tau and TDP-43 aggregation is causative in most of the FTD sub-types.

‘The FDA orphan drug designation of LMTX® is another positive step for patients, clinical researchers and care teams, and it reinforces our continuing research for a disease-modifying treatment for this poorly-addressed family of rare neurodegenerative conditions,’ said Prof. Claude Wischik, Executive Chairman of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen. LMTX® was granted Orphan Designations in this field by the EMA in 2010.

The FDA only grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US, or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. ODD provides an incentive for sponsors to develop products for rare diseases.

About Frontotemporal Dementia  

Frontotemporal dementia (FTD) is a neurodegenerative syndrome characterised by progressive deficits in behaviour, mental function, and language. Behavioural variant FTD (bvFTD) is the most common type of FTD; it is particularly aggressive and progresses faster than Alzheimer”s disease.[1] Symptoms of bvFTD usually start at around 40-60 years of age. The most obvious early symptoms are personality changes, disinhibition, and apathy. This includes socially inappropriate behaviour, impulsive actions, reckless financial decisions and even criminal behaviour.[1] There are currently no treatments available that can affect the progression of FTD. Instead, treatments are aimed at modifying behavioural symptoms.

About TauRx Therapeutics Ltd 

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group which is developing technology spun-out from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company”s tau aggregation inhibitor, LMTX®, targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to ”tau tangles”. LMTX® has also been found to have effects on the aggregation of TDP-43 protein. TauRx”s headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: http://www.taurx.com.

References 

  1. Bang J, et al. (2015) Frontotemporal dementia. Lancet 386:1672-82.

Website: http://www.taurx.com

ABERDEEN, Scotland and SINGAPORE, December 10, 2018 /PRNewswire/ —

Read Full Article

Chinese flower and horticultural consumption has changed over the years, from consumption for big events to consumption on an individual, daily-life basis. The consumption pattern is more personalized and diversified. Although regions such as Yunnan, Shandong, and Guangdong are the main horticultural producers in China, China still requires more high-quality imported variety to meet the needs of consumption.

For both major brands and small businesses to release new products in China, attending Hortiflorexpo IPM Shanghai is a must. The show will bring the latest trends and technologies of flower, horticultural and garden industries to the world again.

Hortiflorexpo IPM is organized by China Flower Association and managed by Shanghai Intex Exhibition and China Great Wall International Exhibition. For 20 years, it has been consistently supported and praised by the industry and has become the most prestigious show in Asia. In 2017, it welcomed close to 800 exhibitors from nearly 30 countries, which were organized into 9 pavilions to exhibit their latest products and ideas.

In 2019, the show will be expanded to 50,000m2, with a larger scale and better-managed overall layout. Exhibits will include flowers, horticulture, floriculture, gardening, outdoor entertainment and relevant supporting products.

A series of fringe programs is again planned for Hortiflorexpo IPM Shanghai 2019. In 2017, the latest trends were shared during flower arrangement shows and industrial forums such as Holland Day, Chinese Technology and Application Research Conference for New Garden Products and Young Plants, Vertical Greening and Sponge City Forum, Nursery Plant Technology Promotion Conference, Home Gardening Forum, and Micro Bonsai Conference.

With the increasingly mature consumer market in China, it is more necessary to strengthen inter-industry and cross-industry exchanges and cooperation between countries and learn from each other. The 21st Hortiflorexpo IPM Shanghai will undoubtedly bring a new wave of ‘green development’ to create an international platform for information exchange, innovation linkage and brand service.

Contact Us:
Shanghai Intex Exhibition Co., Ltd.
Angela Wan: wanqi@shanghai-intex.com 
+862162952075
Xinyi Dong: dongxinyi@shanghai-intex.com 
+862162957551

SHANGHAI, Dec. 1, 2018 /PRNewswire/ — From April 20-22, 2019, Hortiflorexpo IPM Shanghai, the flower and horticulture expo, will be hosted by Shanghai Intex Exhibition at Shanghai New International Expo Center (Hall W2-W5). This will be the 21st edition of the show and will provide 50,000 m2 of floorspace.

Read Full Article